Remove Cell Biology Remove Treatment Remove Trials
article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

The relative ease and lower cost of manufacture (potentially a few thousand dollars) compared to autologous T cell therapies (hundreds of thousands of dollars), coupled with their functional attributes and safety profile, make NK cells an attractive therapeutic option for cancer patients, but surprisingly this is not universally recognised.

Therapies 118
article thumbnail

A research team searches for every gene that helps tumors evade immunotherapy

Broad Institute

By Allessandra DiCorato October 11, 2023 In 2011, Robert Manguso was working in a cell biology lab when his mother was diagnosed with Merkel cell carcinoma, a rare and aggressive skin cancer. By then, a few cancer immunotherapies had entered clinical trials and only a handful had been approved by the FDA.

Research 137
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Building better brain models for Parkinson’s disease and beyond

Drug Target Review

The search for effective treatments for neurodegenerative diseases like Parkinson’s disease has long been hindered by the brain’s complexity and the absence of adequate models for drug discovery. This approach has the potential to revolutionise clinical trial design and lead to more effective, personalised treatments.

Disease 52
article thumbnail

A T cell receptor immunotherapy against a novel target

Drug Target Review

The proof for this came with the approval of KIMMTRAK (tebentafusp-tebn) by the FDA in 2022 for the treatment of HLA-A*02:01+ metastatic or unresectable uveal melanoma, a historically “cold” tumour known to be resistant to current available checkpoint immunotherapies.

article thumbnail

Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance

Drug Target Review

We will explore how GDF-15 impacts the tumour microenvironment and hinders the infiltration of T cells into the tumour, as well as the implications of neutralising GDF-15 to reverse its inhibitory effects and sensitise tumours to anti-PD-1 treatment. T-cell infiltration is a prerequisite for responses to checkpoint inhibitors.

article thumbnail

Cell and gene therapy development moves into cardiac indications

Drug Target Review

Cell and gene therapies (CGTs) have made significant advancements in treating oncological diseases, with therapies like CAR-T cell treatments transforming cancer care. By harvesting, expanding, and injecting CD34+ cells directly to the heart muscle, this natural repair mechanism is enhanced.

article thumbnail

AM-Pharma Appoints Chief Medical Officer and VP Manufacturing to Support Global Pivotal Trial in Sepsis-associated Acute Kidney Injury

The Pharma Data

an emerging leader focused on the treatment of kidney disease, sepsis and organ injury, today announced the appointment of Maarten Kraan, M.D., We welcome them to our team and I am confident in our collective abilities to execute this large late-stage trial enrolling up to 1,600 patients with sepsis and acute kidney injury.”.

Trials 40